IL118239A - Fumarate salt of (R)-5-(methylamino sulphonyl methyl)-3-(N-methyl pyrrolidin-2-ylmethyl)-1 H-indole its preparation and pharmaceutical compositions comprising it - Google Patents

Fumarate salt of (R)-5-(methylamino sulphonyl methyl)-3-(N-methyl pyrrolidin-2-ylmethyl)-1 H-indole its preparation and pharmaceutical compositions comprising it

Info

Publication number
IL118239A
IL118239A IL11823996A IL11823996A IL118239A IL 118239 A IL118239 A IL 118239A IL 11823996 A IL11823996 A IL 11823996A IL 11823996 A IL11823996 A IL 11823996A IL 118239 A IL118239 A IL 118239A
Authority
IL
Israel
Prior art keywords
methyl
ylmethyl
indole
preparation
pharmaceutical compositions
Prior art date
Application number
IL11823996A
Other languages
English (en)
Other versions
IL118239A0 (en
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of IL118239A0 publication Critical patent/IL118239A0/xx
Publication of IL118239A publication Critical patent/IL118239A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL11823996A 1995-05-20 1996-05-13 Fumarate salt of (R)-5-(methylamino sulphonyl methyl)-3-(N-methyl pyrrolidin-2-ylmethyl)-1 H-indole its preparation and pharmaceutical compositions comprising it IL118239A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9510223.2A GB9510223D0 (en) 1995-05-20 1995-05-20 Therapeutic agent

Publications (2)

Publication Number Publication Date
IL118239A0 IL118239A0 (en) 1996-09-12
IL118239A true IL118239A (en) 2000-10-31

Family

ID=10774766

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11823996A IL118239A (en) 1995-05-20 1996-05-13 Fumarate salt of (R)-5-(methylamino sulphonyl methyl)-3-(N-methyl pyrrolidin-2-ylmethyl)-1 H-indole its preparation and pharmaceutical compositions comprising it

Country Status (42)

Country Link
US (1) US5994387A (bg)
EP (1) EP0827503B1 (bg)
JP (1) JP3233940B2 (bg)
KR (1) KR100295255B1 (bg)
CN (1) CN1063175C (bg)
AP (1) AP738A (bg)
AR (1) AR003949A1 (bg)
AT (1) ATE194986T1 (bg)
AU (1) AU701154B2 (bg)
BG (1) BG63046B1 (bg)
BR (1) BR9610858A (bg)
CA (1) CA2219631C (bg)
CO (1) CO5040221A1 (bg)
CZ (1) CZ287939B6 (bg)
DE (1) DE69609504T2 (bg)
DK (1) DK0827503T3 (bg)
DZ (1) DZ2034A1 (bg)
ES (1) ES2148753T3 (bg)
GB (1) GB9510223D0 (bg)
GR (1) GR3034290T3 (bg)
HK (1) HK1017884A1 (bg)
HR (1) HRP960223B1 (bg)
HU (1) HU217657B (bg)
IL (1) IL118239A (bg)
IS (1) IS1908B (bg)
LV (1) LV11992B (bg)
MA (1) MA23876A1 (bg)
MX (1) MX9708966A (bg)
MY (1) MY132066A (bg)
NO (1) NO312068B1 (bg)
NZ (1) NZ306448A (bg)
OA (1) OA10747A (bg)
PL (1) PL183142B1 (bg)
PT (1) PT827503E (bg)
RU (1) RU2161618C2 (bg)
SK (1) SK281782B6 (bg)
TN (1) TNSN96074A1 (bg)
TR (1) TR199701397T1 (bg)
UA (1) UA44320C2 (bg)
WO (1) WO1996036632A1 (bg)
YU (1) YU29496A (bg)
ZA (1) ZA963938B (bg)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
WO2014012859A1 (en) * 2012-07-19 2014-01-23 Boehringer Ingelheim International Gmbh Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3906406C1 (bg) * 1989-03-01 1990-10-25 Goedecke Ag, 1000 Berlin, De
RO111767B1 (ro) * 1990-10-15 1997-01-30 Pfizer Derivati de indol, procedee si intermediari pentru prepararea acestora, compozitii farmaceutice si metoda pentru tratarea unor afectiuni
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.

Also Published As

Publication number Publication date
CO5040221A1 (es) 2001-05-29
CZ364897A3 (cs) 1998-11-11
ATE194986T1 (de) 2000-08-15
IS4605A (is) 1997-10-30
CA2219631C (en) 2001-01-23
IS1908B (is) 2003-12-31
CN1063175C (zh) 2001-03-14
BR9610858A (pt) 1999-07-13
ES2148753T3 (es) 2000-10-16
DK0827503T3 (da) 2000-11-20
HRP960223A2 (en) 1997-10-31
LV11992A (lv) 1998-03-20
BG63046B1 (bg) 2001-02-28
NO312068B1 (no) 2002-03-11
HUP9801761A3 (en) 1999-06-28
PT827503E (pt) 2000-11-30
DE69609504D1 (de) 2000-08-31
RU2161618C2 (ru) 2001-01-10
KR19990014934A (ko) 1999-02-25
MA23876A1 (fr) 1996-12-31
WO1996036632A1 (en) 1996-11-21
DE69609504T2 (de) 2000-12-14
NO975210D0 (no) 1997-11-13
CN1185152A (zh) 1998-06-17
DZ2034A1 (fr) 2002-07-21
PL183142B1 (pl) 2002-05-31
CZ287939B6 (cs) 2001-03-14
BG102053A (bg) 1998-06-30
HUP9801761A2 (hu) 1999-05-28
YU29496A (sh) 1998-12-23
JP3233940B2 (ja) 2001-12-04
HRP960223B1 (en) 2000-12-31
SK154197A3 (en) 1999-01-11
MX9708966A (es) 1998-03-31
PL323143A1 (en) 1998-03-16
SK281782B6 (sk) 2001-07-10
OA10747A (en) 2002-12-11
AU5500596A (en) 1996-11-29
TNSN96074A1 (fr) 2005-03-15
IL118239A0 (en) 1996-09-12
MY132066A (en) 2007-09-28
GB9510223D0 (en) 1995-07-19
UA44320C2 (uk) 2002-02-15
AU701154B2 (en) 1999-01-21
EP0827503B1 (en) 2000-07-26
HK1017884A1 (en) 1999-12-03
HU217657B (hu) 2000-03-28
AP738A (en) 1999-03-23
NO975210L (no) 1997-11-13
JPH10506639A (ja) 1998-06-30
GR3034290T3 (en) 2000-12-29
TR199701397T1 (xx) 1998-03-21
NZ306448A (en) 1998-10-28
ZA963938B (en) 1997-11-17
US5994387A (en) 1999-11-30
AP9600801A0 (en) 1996-04-30
CA2219631A1 (en) 1996-11-21
EP0827503A1 (en) 1998-03-11
LV11992B (en) 1998-06-20
KR100295255B1 (ko) 2001-08-07
AR003949A1 (es) 1998-09-30

Similar Documents

Publication Publication Date Title
HUP0001442A3 (en) Sulfonamide derivatives and pharmaceutical compositions containing them for the treatment of endothelin-mediated disorders
HUP0100737A3 (en) Use of phytosterol for preventing and delaying the onset of alzheimer's disease and phytosterol containing pharmaceutical compositions
HUP0003314A3 (en) Use of glp-1 analogs and derivatives for preparing pharmaceutical compositions useful in regulation of obesity
HUP0400923A3 (en) Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide, process for its preparation, its use and pharmaceutical compositions containing it
EP1045636A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD OF USING THE SAME FOR TREATING FAILURE MYOCARDIAL TISSUES
IL119647A (en) Crystalline modification v of the hydrochloride of (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman, its preparation and a pharmaceutical composition containing it
HUP0001652A3 (en) Oxadiazole derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
HUP0101158A3 (en) Use of glycogen phosphorylase inhibitors for the preparation of pharmaceutical compositions for the prophylactic treatment of type 2 diabetes mellitus
HUP9903489A3 (en) Use of epinastine for the preparation of pharmaceutical compositions treating pain
ZA982609B (en) Pharmaceutical composition for the oral administration of an n-piperidinopyrazole-e-carboxamide derivative its salts and their solvates
HUP9602215A3 (en) Use of 4-chloro-5-(imidazolyn-2-yl-amino)-6-methoxy-2-methylpyrimidine for producing pharmaceutical composition useful intreating substance abuse withdrawal
HUP9901096A3 (en) Indole derivatives, preparation and use thereof, pharmaceutical composition containing these compounds
IL117620A0 (en) Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0100024A3 (en) Pharmaceutical compositions for treating alzheimer's disease containing carvedilol as active ingredient
HUP0000960A3 (en) Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same
IL109376A (en) Pharmaceutical composition containing (R)-5-(methyl-aminosulfonylmethyl)-3-(N-methylpyrrolidin-2-yl-methyl)-1H-indole and (R)-5-(methylamino-sulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole
HUP0004331A3 (en) Use of phanquinone for producing pharmaceutical compositions for the treatment of alzheimer's disease and combined pharmaceutical compositions containing it
HUP0004648A3 (en) 3-substituted tetrahydropyridopyrimidinone derivatives and their use for producing pharmaceutical compositions
IL118239A (en) Fumarate salt of (R)-5-(methylamino sulphonyl methyl)-3-(N-methyl pyrrolidin-2-ylmethyl)-1 H-indole its preparation and pharmaceutical compositions comprising it
HUP0102836A3 (en) Use of oxazolidinones for preparation of pharmaceutical compositions suitable for treating eye infections
IL121096A0 (en) Pharmaceutical compositions for the treatment of liver disease
NZ307370A (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
WO2001005386A3 (en) Pharmaceutical composition useful for the treatment of tinnitus and hearing loss
HUP0400889A3 (en) Processes for the preparation of (r)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and pharmaceutical compositions containing the compound
HUP0003634A3 (en) Use of thiazolidinedione and sulphonylurea derivatives for the preparation of pharmaceutical compositions treating diabetes

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB20 Patent renewed for 20 years
MM9K Patent not in force due to non-payment of renewal fees